Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $48.8 million.

  • Viking Therapeutics' Change in Account Payables rose 41080.43% to $48.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $43.4 million, marking a year-over-year increase of 178614.85%. This contributed to the annual value of $43.4 million for FY2025, which is 178614.85% up from last year.
  • As of Q4 2025, Viking Therapeutics' Change in Account Payables stood at $48.8 million, which was up 41080.43% from -$1.1 million recorded in Q3 2025.
  • Over the past 5 years, Viking Therapeutics' Change in Account Payables peaked at $48.8 million during Q4 2025, and registered a low of -$10.8 million during Q3 2024.
  • Its 5-year average for Change in Account Payables is $2.5 million, with a median of -$268500.0 in 2021.
  • As far as peak fluctuations go, Viking Therapeutics' Change in Account Payables surged by 56373.63% in 2022, and later tumbled by 1093500.0% in 2024.
  • Over the past 5 years, Viking Therapeutics' Change in Account Payables (Quarter) stood at -$1.4 million in 2021, then soared by 487.55% to $5.4 million in 2022, then plummeted by 66.57% to $1.8 million in 2023, then skyrocketed by 430.87% to $9.6 million in 2024, then soared by 410.8% to $48.8 million in 2025.
  • Its Change in Account Payables stands at $48.8 million for Q4 2025, versus -$1.1 million for Q3 2025 and -$2.2 million for Q2 2025.